Role of Oligodendrocyte Lineage Cells in Multiple System Atrophy.
Jen-Hsiang T HsiaoOnur TanglayAnne A LiAysha Y G StrobbeWoojin Scott KimGlenda M HallidayYuHong FuPublished in: Cells (2023)
Multiple system atrophy (MSA) is a debilitating movement disorder with unknown etiology. Patients present characteristic parkinsonism and/or cerebellar dysfunction in the clinical phase, resulting from progressive deterioration in the nigrostriatal and olivopontocerebellar regions. MSA patients have a prodromal phase subsequent to the insidious onset of neuropathology. Therefore, understanding the early pathological events is important in determining the pathogenesis, which will assist with developing disease-modifying therapy. Although the definite diagnosis of MSA relies on the positive post-mortem finding of oligodendroglial inclusions composed of α-synuclein, only recently has MSA been verified as an oligodendrogliopathy with secondary neuronal degeneration. We review up-to-date knowledge of human oligodendrocyte lineage cells and their association with α-synuclein, and discuss the postulated mechanisms of how oligodendrogliopathy develops, oligodendrocyte progenitor cells as the potential origins of the toxic seeds of α-synuclein, and the possible networks through which oligodendrogliopathy induces neuronal loss. Our insights will shed new light on the research directions for future MSA studies.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- induced apoptosis
- chronic kidney disease
- prognostic factors
- healthcare
- endothelial cells
- cell cycle arrest
- parkinson disease
- oxidative stress
- stem cells
- patient reported outcomes
- single cell
- bone marrow
- human health
- cell therapy
- subarachnoid hemorrhage
- patient reported
- pi k akt